PSMA PET/CT impact on upstaging and reducing equivocal findings in prostate cancer

Declan G. Murphy, MB BCh, Peter MacCallum Cancer Centre, Victoria, Australia, discusses the impact of PSMA PET/CT in regard to the upstaging of prostate cancer and lowering the rate of equivocal findings.

Murphy was the senior author of the phase 3 proPSMA study, which examined Ga 68 PSMA-1 in patients with high-risk prostate cancer before curative-intent surgery. The study demonstrated that Ga 68 PSMA-1 had better accuracy, sensitivity, and specificity than convention imaging.

In the video, which was shot during the 2020 SUO Annual Meeting, Murphy describes how the accuracy of PSMA PET/CT reduced the rate of equivocal findings in the proPSMA study. The rates were 6%-7% in the PSMA PET/CT arm compared with 23% in patients who received standard CT/bone scans.